Development of ipilimumab: A novel immunotherapeutic approach for the treatment of advanced melanoma

Annals of the New York Academy of Sciences

Volumn 1291, Issue 1, 2013, Pages 1-13

  Wolchok, Jedd D ^a   Hodi, F Stephen ^b   Weber, Jeffrey S ^c   Allison, James P ^d   Urba, Walter J ^e   Robert, Caroline ^f   O'Day, Steven J ^g   Hoos, Axel ^h   Humphrey, Rachel ⁱ   Berman, David M ^j   Lonberg, Nils ^k   Korman, Alan J ^k  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e EARLE A CHILES RESEARCH INSTITUTE   (United States)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g Beverly Hills Cancer Center   (United States)

^h GLAXOSMITHKLINE   (United States)

ⁱ METHYLGENE INC   (Canada)

^j BRISTOL MYERS SQUIBB   (United States)

^k Bristol Myers Squibb   (United States)

more..

Author keywords

Cytotoxic T lymphocyte antigen 4; Immuno oncology; Immunotherapy; Ipilimumab; Melanoma; Monoclonal antibody

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; FOTEMUSTINE; GLYCOPROTEIN GP 100; IPILIMUMAB; TEMOZOLOMIDE; TICILIMUMAB; VEMURAFENIB;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; COLITIS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FOLLOW UP; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; INNATE IMMUNITY; METASTATIC MELANOMA; NONHUMAN; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRURITUS; RASH;

EID: 84880511594     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12180     Document Type: Article

References (91)

1. American Cancer Society. Cancer Facts & Figures 2013. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf
2. Jemal, A., R. Siegel, J. Xu & E. Ward. 2010. Cancer statistics, 2010. CA Cancer J. Clin. 60: 277-300.
3. Korn, E.L. et al. 2008. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J. Clin. Oncol. 26: 527-534.
4. Garbe, C., T.K. Eigentler, U. Keilholz, et al. 2011. Systematic review of medical treatment in melanoma: current status and future perspectives. Oncologist 16: 5-24.
5. Sloan, A.E., C.J. Nock & D.B. Einstein. 2009. Diagnosis and treatment of melanoma brain metastases: a literature review. Cancer Control 16: 248-255.
6. Agarwala, S.S. 2010. Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma. Melanoma Res. 20: 1-10.
7. Eggermont, A.M. & J.M. Kirkwood. 2004. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur. J. Cancer 40: 1825-1836.
8. Rosenberg S.A. 2012. Raising the bar: the curative potential of human caner immunotherapy. Sci. Transl. Med. 4: 127ps8.
9. Eggermont, A.M. 2010. Advances in systemic treatment of melanoma. Ann. Oncol. 21 (Suppl 7): vii339-vii344.
10. Hoos, A. et al. 2010. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin. Oncol. 37: 533-546.
11. Sharma, P., K. Wagner, J.D. Wolchok & J.P. Allison. 2011. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat. Rev. Cancer 11: 805-812.
12. Tarhini, AA. 2013. Tremelimumab: a review of development to date in solid tumors. Immunotherapy 5: 215-229.
13. Hodi, F.S. et al. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363: 711-723.
14. Robert, C. et al. 2011. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364: 2517-2526.
15. Ribas, A. et al. 2013. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 31: 616-622.
16. Hoos, A. et al. 2010. Improved endpoints for cancer immunotherapy trials. J. Natl. Cancer Inst. 102: 1388-1397.
17. Eggermont, A.M. & C. Robert. 2011. New drugs in melanoma: it's a whole new world. Eur. J. Cancer 47: 2150-2157.
18. Shaw, H.M. & P.D. Nathan. 2013. Vemurafenib in melanoma. Expert Rev. Anticancer Ther. 13: 513-522.
19. McCarthy, E.F. 2006. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop. J. 26: 154-158.
20. Lippman, S.M. & E.T. Hawk. 2009. Cancer prevention: from 1727 to milestones of the past 100 years. Cancer Res. 69: 5269-5284.
21. Waldmann, T.A. 2003. Immunotherapy: past, present and future. Nat. Med. 9: 269-277.
22. Burnett, F.M. 1970. The concept of immunological surveillance. Prog. Exp. Tumor Res. 13: 1-27.
23. Lockyer, C.R. & D.A. Gillatt. 2001. BCG immunotherapy for superficial bladder cancer. J. R. Soc. Med. 94: 119-123.
24. Finn, O.J. 2012. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann. Oncol. 23 (Suppl 8): viii6-viii9.
25. Melero, I., S. Hervas-Stubbs, M. Glennie, et al. 2007. Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer 7: 95-106.
26. de Visser, K.E., A. Eichten & L.M. Coussens. 2006. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 6: 24-37.
27. Abrams, S.I. 2004. Regulation of tumor progression by anti-neoplastic T cell responses. Cancer Biol. Ther. 3: 140-146.
28. Caligiuri, M.A. 2008. Human natural killer cells. Blood 112: 461-469.
29. Korman, A.J., K.S. Peggs & J.P. Allison. 2006. Checkpoint blockade in cancer immunotherapy. Adv. Immunol. 90: 297-339.
30. + T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10: 29-37.
31. DeVita, V.T. Jr. & S.A. Rosenberg. 2012. Two hundred years of cancer research. N. Engl. J. Med. 366: 2207-2214.
32. Hanahan, D. & R.A. Weinberg. 2011. Hallmarks of cancer: the next generation. Cell 144: 646-647.
33. Finn, O.J. 2008. Cancer immunology. N. Engl. J. Med. 358: 2704-2715.
34. Reiman, J.M., M. Kmieciak, M.H. Manjili & K.L. Knutson. 2007. Tumor immunoediting and immunosculpting pathways to cancer progression. Semin. Cancer Biol. 17: 275-287.
35. Hoos, A., C.M. Britten, C. Huber & J. O'Donnell-Tormey. 2011. A methodological framework to enhance the clinical success of cancer immunotherapy. Nat. Biotechnol. 29: 867-870.
36. Allison, J.P. & M.F. Krummel. 1995. The Yin and Yang of T cell costimulation. Science 270: 932-933.
37. Krummel, M.F. & J.P. Allison. 1996. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 183: 2533-2540.
38. Peggs, K.S., S.A. Quezada, A.J. Korman & J.P. Allison. 2006. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr. Opin. Immunol. 18: 206-213.
39. Tarhini, A.A. & F. Iqbal. 2010. CTLA-4 blockade: therapeutic potential in cancer treatments. Oncol. Targets Ther. 3: 15-25.
40. Krummel, M.F. & J.P. Allison. 1995. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182: 459-465.
41. Tivol, E.A. et al. 1995. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3: 541-547.
42. Waterhouse, P. et al. 1995. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270: 985-988.
43. Leach, D.R., M.F. Krummel & J.P. Allison. 1996. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271: 1734-1736.
44. Mokyr, M.B., T. Kalinichenko, L. Gorelik & J.A. Bluestone. 1998. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. Cancer Res. 58: 5301-5304.
45. van Elsas, A., A.A. Hurwitz & J.P. Allison. 1999. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190: 355-366.
46. Keler, T. et al. 2003. Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques. J. Immunol. 171: 6251-6259.
47. Maker, A.V. et al. 2005. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann. Surg. Oncol. 12: 1005-1016.
48. Attia, P. et al. 2005. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 23: 6043-6053.
49. Hersh, E.M. et al. 2011. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest. N. Drugs 29: 489-498.
50. Slovin, S.F. et al. 2013. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann. Oncol. Mar 27. DOI: 10.1093/annonc/mdt107.
51. Weber, J. et al. 2009. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin. Cancer Res. 15: 5591-5598.
52. Wolchok, J.D. et al. 2010. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 11: 155-164.
53. O'Day, S.J. et al. 2010. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter, single-arm, phase II study. Ann. Oncol. 21: 1712-1717.
54. Hamid, O. et al. 2011. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J. Transl. Med. 9: 204.
55. Weber, J.S. et al. 2012. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma. J. Immunother. 35: 89-97.
56. Dancygier, H., U. Runne, U. Leuschner, et al. 1983. Dacarbazine (DTIC)-induced human liver damage light and electron-microscopic findings. Hepatogastroenterology 30: 93-95.
57. Frosch, P.J., B.M. Czarnetzki, E. Macher, et al. 1979. Hepatic failure in a patient treated with dacarbazine (DTIC) for malignant melanoma. J. Cancer Res. Clin. Oncol. 95: 281-286.
58. Chapman, P.B. et al. 2011. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364: 2507-2516.
59. Shahabi, V. et al. 2012. Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab. Cancer Immunol. Immunother. 61: 733-737.
60. Margolin, K. et al. 2012. Ipilimumab in patients with melanoma and brain metastases. Lancet Oncol. 13: 459-465.
61. Di Giacomo, A.M. et al. 2012. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol. 13: 879-886.
62. Lebbé, C. et al. 2012. Five-year survival rates for patients (pts) with metastatic melanoma (MM) treated with ipilimumab (IPI) in phase II trials. Ann. Oncol. 23(9 Suppl): abstract 1116PD.
63. Prieto, P.A. et al. 2012. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin. Cancer Res. 18: 2039-2047.
64. Maio, M. et al. 2012. Four-year survival update for metastatic melanoma (MM) patients (pts) treated with ipilimumab (IPI) plus dacarbazine (DTIC) in phase III study CA184-024. Ann. Oncol. 23(9 Suppl): abstract 1127P.
65. Weber, J.S., K.C. Kahler & A. Hauschild. 2012. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 30: 2691-2697.
66. TM Full Prescribing Information. http://packageinserts.bms.com/pi/pi_yervoy.pdf
67. Kaehler, K.C. et al. 2010. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin. Oncol. 37: 485-498.
68. Pennock, G.K., W. Waterfield & J.D. Wolchok. 2011. Patient responses to Ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses? Am. J. Clin. Oncol. 35: 606-611.
69. Ribas, A., B. Chmielowski & J.A. Glaspy. 2009. Do we need a different set of response assessment criteria for tumor immunotherapy? Clin. Cancer Res. 15: 7116-7118.
70. Wolchok, J.D. et al. 2009. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15: 7412-7420.
71. Miller, A.B., B. Hoogstraten, M. Staquet & A. Winkler. 1981. Reporting results of cancer treatment. Cancer 47: 207-214.
72. Eisenhauer, E.A. et al. 2009. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45: 228-247.
73. Lynch, T.J. et al. 2012. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J. Clin. Oncol. 30: 2046-2054.
74. ClinicalTrials.gov. Phase 3 trial in subjects with metastatic melanoma comparing 3 mg/kg ipilimumab versus 10 mg/kg ipilimumab (NCT01515189). http://www.clinicaltrials.gov/ct2/show/NCT01515189
75. ClinicalTrials.gov. A phase I/II trial of vemurafenib and ipilimumab in subjects with V600 BRAF mutation-positive metastatic melanoma (NCT01400451). http://www. clinicaltrials.gov/ct2/show/NCT01400451
76. ClinicalTrials.gov. Phase II safety study of vemurafenib followed by ipilimumab in subjects with V600 BRAF mutated advanced melanoma (NCT01673854). http://www. clinicaltrials.gov/ct2/show/NCT01673854
77. Agarwala, S.S. & S.J. O'Day. 2010. Current and future adjuvant immunotherapies for melanoma: blockade of cytotoxic T-lymphocyte antigen-4 as a novel approach. Cancer Treat. Rev. 37: 133-142.
78. ClinicalTrials.gov. Ipilimumab or high-dose interferon alfa-2b in treating patients with high-risk stage III or stage IV melanoma that has been removed by surgery (NCT01274338). http://www.clinicaltrials.gov/ct2/show/NCT01274338
79. Burnette, B., Y.X. Fu & R.R. Weichselbaum. 2012. The confluence of radiotherapy and immunotherapy. Front. Oncol. 2: 143.
80. Harris, T.J. et al. 2008. Radiotherapy augments the immune response to prostate cancer in a time-dependent manner. Prostate 68: 1319-1329.
81. Postow, M.A. et al. 2012. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366: 925-931.
82. ClinicalTrials.gov. A phase II study to evaluate safety and efficacy of combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma (NCT01480323). http://www.clinicaltrials. gov/ct2/show/NCT01480323
83. Topalian, S.L. et al. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366: 2443-2454.
84. ClinicalTrials.gov. Dose-escalation study of combination BMS-936558 (MDX-1106) and ipilimumab in subjects with unresectable stage III or stage IV malignant melanoma (NCT01024231). http://www.clinicaltrials.gov/ct2/show/NCT01024231
85. Murala, S., V. Alli, K. Kreisel, et al. 2010. Current status of immunotherapy for the treatment of lung cancer. J. Thorac. Dis. 2: 237-244.
86. Reck, M. et al. 2013. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann. Oncol. 24: 75-83.
87. ClinicalTrials.gov. Trial in extensive-disease small cell lung cancer (ED-SCLC) subjects comparing ipilimumab plus etoposide and platinum therapy to etoposide and platinum therapy alone(NCT01450761). http://www. clinicaltrials.gov/ct2/show/NCT01450761
88. ClinicalTrials.gov. Trial in squamous non small cell lung cancer subjects comparing ipilimumab plus paclitaxel and carboplatin versus placebo plus paclitaxel and carboplatin (NCT01285609). http://www.clinicaltrials. gov/ct2/show/NCT01285609
89. ClinicalTrials.gov. A phase II efficacy and safety study of ipilimumab monotherapy following completion of chemotherapy in recurrent platinum sensitive ovarian cancer subjects with residual measurable disease (NCT01611558). http://www.clinicaltrials.gov/ct2/show/NCT01611558
90. ClinicalTrials.gov. An efficacy study in gastric and gastroesophageal junction cancer comparing ipilimumab versus standard of care immediately following first line chemotherapy (NCT01585987). http://www.clinicaltrials. gov/ct2/show/NCT01585987
91. ClinicalTrials.gov. Phase II trial of gemcitabine, cisplatin, plus ipilimumab as first-line treatment for patients with metastatic urothelial carcinoma: Hoosier Oncology Group GU10-148 (NCT01524991). http://www.clinicaltrials.gov/ct2/show/NCT01524991